Core Viewpoint - TianTan Biological experienced a sharp increase in stock price, reaching the daily limit, while other companies in the sector such as Keta Bio, Nanmo Bio, and Sairun Bio saw their stock prices rise by over 10% [1] Company Performance - TianTan Biological's stock price hit the daily limit, indicating strong market interest and confidence in the company [1] - Keta Bio, Nanmo Bio, and Sairun Bio also showed significant gains, with stock prices increasing by more than 10%, reflecting positive sentiment in the biotechnology sector [1] - Watson Bio and Anxu Bio, among others, followed suit with notable increases in their stock prices, suggesting a broader rally in the biotechnology industry [1]

8月4日突破年线个股乖离率排名 证券时报·数据宝统计，截至今日下午13:59，上证综指3568.96点，收于年线之上，涨跌幅为0.25%，A 股总成交额为11803.88亿元。到目前为止，今日有28只A股价格突破了年线，其中乖离率较大的个股有 天坛生物、光弘科技、中信海直等，乖离率分别为5.23%、4.69%、4.50%；桂冠电力、艾布鲁、蓝箭电 子等个股乖离率较小，刚刚站上年线。 （文章来源：证券时报网） | | 能 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 301587 | 中瑞股 | 1.04 | 1.39 | 23.33 | 23.38 | 0.22 | | | 份 | | | | | | | 300699 | 光威复 | 1.74 | 1.42 | 30.89 | 30.95 | 0.19 | | | 材 | | | | | | | 688337 | 普源精 | 2.21 | 3.39 | 35.10 | 35.16 | 0.16 | | | 电 | | | | | | | 300956 | 英力股 | 1.1 1 | 1.5 ...

Core Viewpoint - The A-share market saw a significant rise in biopharmaceutical stocks, particularly with notable gains from companies such as Nanmo Bio and Sairun Bio, following the completion of China's first Phase I clinical trial for an HIV vaccine using a modified smallpox virus as a carrier [1] Group 1: Market Performance - Biopharmaceutical stocks in the A-share market experienced a surge, with Nanmo Bio and Sairun Bio rising over 14% [1] - Tiantan Biological (600161) hit the daily limit with a 10% increase [1] - Other companies such as Zhijiang Bio, Watson Bio (300142), Rendu Bio, and Anxu Bio also saw gains [1] Group 2: Research and Development - The Chinese Center for Disease Control and Prevention's AIDS Prevention Center completed the first Phase I clinical trial for a replicative Tian Tan smallpox vaccine-based HIV vaccine [1] - The innovative research utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a carrier [1] - The trial confirmed the safety of the vaccine and its ability to elicit an effective immune response, marking a significant advancement in HIV vaccine development in China [1]

Group 1 - The core viewpoint of the article highlights the significant progress made in HIV vaccine research in China, with the completion of the first Phase I clinical trial of a recombinant Tian Tan smallpox vaccine-based HIV vaccine [1] - The innovative approach utilizes the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a vector for the vaccine, demonstrating safety and the ability to elicit an effective immune response [1] - Following this announcement, the A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting the daily limit of 10% [1]

（文章来源：每日经济新闻） 每经AI快讯，8月4日，天坛生物直线拉升涨停，科拓生物、南模生物、赛伦生物涨超10%，沃森生物、 安旭生物等跟涨。 ...

人民财讯8月4日电，生物制品板块拉升，天坛生物涨停，万泽股份此前封板，艾迪药业、智飞生物、博 雅生物、博晖创新、派林生物等跟涨。 （原标题：生物制品板块拉升 天坛生物涨停） ...

Group 1 - The A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting a 10% limit up [1] - The China CDC and other teams completed the first Phase I clinical trial of a replicative Tian Tan smallpox vaccine-based HIV vaccine, marking a significant advancement in HIV vaccine research in China [1] - The innovative approach utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, to verify the safety and effective immune response of the vaccine [1]

Group 1 - The A-share biopharmaceutical sector experienced a short-term surge, with Tian Tan Biological reaching the daily limit, and Wan Ze Shares previously hitting the limit as well [1] - Other companies such as Aidi Pharmaceutical, Zhifei Biological, Boya Biological, Bohui Innovation, and Pailin Biological also saw increases in their stock prices [1] - The news is driven by the completion of China's first copy-type Tian Tan smallpox vaccine carrier HIV vaccine Phase I clinical trial by teams from the Chinese Center for Disease Control and Prevention and the AIDS Prevention Center [1]

Group 1 - The biopharmaceutical sector experienced a short-term surge, with TianTan Bio reaching the daily limit increase [1] - WanZe Co. previously hit the limit up, indicating strong market interest [1] - Other companies such as Aidi Pharmaceutical, ZhiFei Biological, BoYa Bio, BoHui Innovation, and PaiLin Bio also saw significant gains [1]

金融界消息 截至2025年8月1日收盘，天坛生物（600161）报收于20.07元，上涨0.25%，换手率0.8%， 成交量15.79万手，成交金额3.19亿元。 资金流向方面，今日主力资金净流入2299.73万元，占比成交额7.2%。其中，超大单净流入1383.71万 元、占成交额4.33%，大单净流入916.02万元、占成交额2.87%，中单净流出流出1423.11万元、占成交 额4.46%，小单净流出876.62万元、占成交额2.75%。 天坛生物最新一期业绩显示，截至2025一季报，公司营业总收入13.18亿元、同比增长7.84%，归属净利 润2.44亿元，同比减少22.90%，扣非净利润2.39亿元，同比减少23.71%，流动比率7.188、速动比率 3.627、资产负债率8.41%。 天眼查商业履历信息显示，北京天坛生物制品股份有限公司，成立于1998年，位于北京市，是一家以从 事医药制造业为主的企业。企业注册资本197737.1446万人民币，实缴资本197737.1446万人民币。公司 法定代表人为何彦林。 通过天眼查大数据分析，北京天坛生物制品股份有限公司共对外投资了4家企业，参与招投标项目 ...